Stock ALSMA SMAIO
Add to a list
To use this feature you must be a member
Log inSign up

Financials SMAIO

Equities

ALSMA

FR0014005I80

Pharmaceuticals

Real-time Euronext Paris
Other stock markets
 06:14:43 2024-05-29 am EDT 		5-day change 1st Jan Change
3.7 EUR +1.65% Intraday chart for SMAIO +5.71% +20.13%
Jan. 23 S.M.A.I.O S.A. Announces Unaudited Group Sales Results for the Year Ended December 31, 2023 CI
2023 S.M.A.I.O S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2022 2023 2024 2025
Capitalization 1 16.99 19.03 19.03 -
Enterprise Value (EV) 1 11.95 16.1 18.73 20.33
P/E ratio - -13.5 x -9.33 x 36.4 x
Yield - - - -
Capitalization / Revenue 7.08 x 2.99 x 3.52 x 1.85 x
EV / Revenue 4.98 x 2.99 x 3.47 x 1.97 x
EV / EBITDA -4.7 x -52.4 x -15.6 x 14.5 x
EV / FCF 2.34 x -9.25 x -5.51 x -12 x
FCF Yield 42.7% -10.8% -18.2% -8.36%
Price to Book - - - -
Nbr of stocks (in thousands) 5,229 5,229 5,229 -
Reference price 2 3.250 3.640 3.640 3.640
Announcement Date 4/11/23 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025
Net sales 1 2.1 2.4 5.383 5.4 10.3
EBITDA 1 - -2.544 -0.3 -1.2 1.4
EBIT 1 - -4 -1.7 -2.4 0.2
Operating Margin - -166.67% -30.91% -44.44% 1.94%
Earnings before Tax (EBT) - - - - -
Net income 1 -3.1 2.846 -1.4 -2 0.5
Net margin -147.62% 118.57% -25.45% -37.04% 4.85%
EPS 2 - - -0.2700 -0.3900 0.1000
Free Cash Flow 1 - 5.106 -1.7 -3.4 -1.7
FCF margin - 212.73% -30.91% -62.96% -16.5%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - 179.42% - - -
Dividend per Share - - - - -
Announcement Date 4/29/22 4/11/23 - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025
Net Debt 1 - - - - 1.3
Net Cash position 1 - 5.04 3.3 0.3 -
Leverage (Debt/EBITDA) - - - - 0.9286 x
Free Cash Flow 1 - 5.11 -1.7 -3.4 -1.7
ROE (net income / shareholders' equity) - 29.2% - - 5.8%
ROA (Net income/ Total Assets) - - - - 4.6%
Assets 1 - - - - 10.87
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex 1 - 0.83 1 1.5 1.5
Capex / Sales - 34.59% 18.18% 27.78% 14.56%
Announcement Date 4/29/22 4/11/23 - - -
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for SMAIO

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.64 EUR
Average target price
5.8 EUR
Spread / Average Target
+59.34%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SMAIO Stock SMAIO
+20.13% 20.7M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.59% 727B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.89% 347B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.66% 319B
ABBVIE INC. Stock AbbVie Inc.
+0.24% 274B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.25% 238B
NOVARTIS AG Stock Novartis AG
+7.13% 204B
ROCHE HOLDING AG Stock Roche Holding AG
-6.26% 203B
AMGEN INC. Stock Amgen Inc.
+4.23% 161B
PFIZER, INC. Stock Pfizer, Inc.
-1.70% 160B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ALSMA Stock
  4. Financials SMAIO